Eli Lilly and Company $LLY Shares Sold by ZWJ Investment Counsel Inc.

ZWJ Investment Counsel Inc. lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.7% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,347 shares of the company’s stock after selling 47 shares during the quarter. ZWJ Investment Counsel Inc.’s holdings in Eli Lilly and Company were worth $4,948,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Family CFO Inc acquired a new stake in Eli Lilly and Company in the second quarter valued at approximately $54,000. Duquesne Family Office LLC grew its position in Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after acquiring an additional 32,640 shares in the last quarter. Corient IA LLC acquired a new stake in Eli Lilly and Company in the first quarter valued at approximately $570,000. Cutter Capital Management LP acquired a new stake in Eli Lilly and Company in the first quarter valued at approximately $14,866,000. Finally, Emerald Advisors LLC grew its position in Eli Lilly and Company by 60.8% in the second quarter. Emerald Advisors LLC now owns 1,021 shares of the company’s stock valued at $796,000 after acquiring an additional 386 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on LLY. Morgan Stanley lowered their price objective on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research report on Friday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Saturday, September 27th. UBS Group lowered their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Berenberg Bank reaffirmed a “hold” rating and issued a $830.00 price objective (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Finally, Daiwa Capital Markets cut Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price for the company. in a research note on Sunday, August 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $933.39.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $840.46 on Friday. The stock has a market cap of $795.47 billion, a P/E ratio of 54.93, a price-to-earnings-growth ratio of 1.14 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a 50 day moving average of $734.60 and a 200-day moving average of $766.47. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the prior year, the business posted $3.92 EPS. The business’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson acquired 200 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was purchased at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Daniel Skovronsky acquired 1,000 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares of the company’s stock, valued at $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,514 shares of company stock valued at $2,894,841 over the last quarter. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.